Venetis K et al. [90] analysed the role of ctDNA for detecting ESR1 mutations and their implications for tailoring effective therapeutic strategies for HR+/HER2− metastatic BC, emphasising that ctDNA analysis is a minimally invasive method for the detection of ESR1 mutation [90]. This evidence concerns the gene ESR1 and breast cancer.